within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BX17_RosuvastatinAndRamipril;

model RosuvastatinAndRamipril
  extends Pharmacolibrary.Drugs.ATC.C.C10BX17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10BX17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rosuvastatin and ramipril are used in combination therapy for cardiovascular risk reduction; rosuvastatin is a statin used to lower cholesterol and ramipril is an ACE inhibitor used for hypertension and heart failure. The fixed combination is approved in some countries for patients requiring both treatments.</p><h4>Pharmacokinetics</h4><p>No published population pharmacokinetic studies or dedicated PK study specific for the fixed-dose combination C10BX17. Estimates are based on the known oral pharmacokinetics of rosuvastatin and ramipril individually in healthy adults.</p><h4>References</h4><ol><li><p>Ferri, N, &amp; Corsini, A (2025). [Clinical pharmacology of combination therapies for the prevention and treatment of cardiovascular diseases]. <i>Giornale italiano di cardiologia (2006)</i> 26(1 Suppl 2) e6â€“e16. DOI:<a href=&quot;https://doi.org/10.1714/4425.44225&quot;>10.1714/4425.44225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39898749/&quot;>https://pubmed.ncbi.nlm.nih.gov/39898749</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RosuvastatinAndRamipril;
